APO Research
Talk to an analyst

APO RESEARCH · REPORT

Treatment for Accelerated-Phase CML

Compare research editions
View pricing & licenses

Selected research

Industry Research

Treatment for Accelerated-Phase CML Industry Research Report 2026

27 December 2025125 pages

Choose your research edition.

Industry ResearchTreatment for Accelerated-Phase CML Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Treatment for Accelerated-Phase CML Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Treatment for Accelerated-Phase CML Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Treatment for Accelerated-Phase CML Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Treatment for Accelerated-Phase CML Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Treatment for Accelerated-Phase CML market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Treatment for Accelerated-Phase CML is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Treatment for Accelerated-Phase CML is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Treatment for Accelerated-Phase CML is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Treatment for Accelerated-Phase CML include Apotex, Bristol Myers Squibb, Dr. Reddy's Laboratories, Novartis, Pfizer, Takeda Pharmaceuticals, Lunan Pharmaceutical, Qilu Pharmaceutical and CSPC Ouyi Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Treatment for Accelerated-Phase CML market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Treatment for Accelerated-Phase CML Market by Company

Apotex

Bristol Myers Squibb

Dr. Reddy's Laboratories

Novartis

Pfizer

Takeda Pharmaceuticals

Lunan Pharmaceutical

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Treatment for Accelerated-Phase CML Segment by Type

Tyrosine Kinase Inhibitors

Allogeneic Stem Cell Transplantation

Others

Treatment for Accelerated-Phase CML Segment by Application

Hospitals

Clinics

Others

Treatment for Accelerated-Phase CML Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatment for Accelerated-Phase CML market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Treatment for Accelerated-Phase CML and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatment for Accelerated-Phase CML.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Treatment for Accelerated-Phase CML manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Treatment for Accelerated-Phase CML by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Treatment for Accelerated-Phase CML in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Treatment for Accelerated-Phase CML Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Treatment for Accelerated-Phase CML Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Treatment for Accelerated-Phase CML Sales Market Share by Manufacturers (2021-2026) Table 8. Global Treatment for Accelerated-Phase CML Revenue of Manufacturers (2021-2026) Table 9. Global Treatment for Accelerated-Phase CML Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Treatment for Accelerated-Phase CML Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Treatment for Accelerated-Phase CML Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Treatment for Accelerated-Phase CML, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Treatment for Accelerated-Phase CML, Product Type & Application Table 14. Global Treatment for Accelerated-Phase CML Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Treatment for Accelerated-Phase CML by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Apotex Company Information Table 19. Apotex Business Overview Table 20. Apotex Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Apotex Treatment for Accelerated-Phase CML Product Portfolio Table 22. Apotex Recent Developments Table 23. Bristol Myers Squibb Company Information Table 24. Bristol Myers Squibb Business Overview Table 25. Bristol Myers Squibb Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bristol Myers Squibb Treatment for Accelerated-Phase CML Product Portfolio Table 27. Bristol Myers Squibb Recent Developments Table 28. Dr. Reddy's Laboratories Company Information Table 29. Dr. Reddy's Laboratories Business Overview Table 30. Dr. Reddy's Laboratories Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Dr. Reddy's Laboratories Treatment for Accelerated-Phase CML Product Portfolio Table 32. Dr. Reddy's Laboratories Recent Developments Table 33. Novartis Company Information Table 34. Novartis Business Overview Table 35. Novartis Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Novartis Treatment for Accelerated-Phase CML Product Portfolio Table 37. Novartis Recent Developments Table 38. Pfizer Company Information Table 39. Pfizer Business Overview Table 40. Pfizer Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Pfizer Treatment for Accelerated-Phase CML Product Portfolio Table 42. Pfizer Recent Developments Table 43. Takeda Pharmaceuticals Company Information Table 44. Takeda Pharmaceuticals Business Overview Table 45. Takeda Pharmaceuticals Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Takeda Pharmaceuticals Treatment for Accelerated-Phase CML Product Portfolio Table 47. Takeda Pharmaceuticals Recent Developments Table 48. Lunan Pharmaceutical Company Information Table 49. Lunan Pharmaceutical Business Overview Table 50. Lunan Pharmaceutical Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Lunan Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio Table 52. Lunan Pharmaceutical Recent Developments Table 53. Qilu Pharmaceutical Company Information Table 54. Qilu Pharmaceutical Business Overview Table 55. Qilu Pharmaceutical Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Qilu Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio Table 57. Qilu Pharmaceutical Recent Developments Table 58. CSPC Ouyi Pharmaceutical Company Information Table 59. CSPC Ouyi Pharmaceutical Business Overview Table 60. CSPC Ouyi Pharmaceutical Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. CSPC Ouyi Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio Table 62. CSPC Ouyi Pharmaceutical Recent Developments Table 63. Chia Tai Tianqing Pharmaceutical Company Information Table 64. Chia Tai Tianqing Pharmaceutical Business Overview Table 65. Chia Tai Tianqing Pharmaceutical Treatment for Accelerated-Phase CML Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Chia Tai Tianqing Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio Table 67. Chia Tai Tianqing Pharmaceutical Recent Developments Table 68. Global Treatment for Accelerated-Phase CML Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global Treatment for Accelerated-Phase CML Sales by Region (2021-2026) & (K Units) Table 70. Global Treatment for Accelerated-Phase CML Sales Market Share by Region (2021-2026) Table 71. Global Treatment for Accelerated-Phase CML Sales by Region (2027-2032) & (K Units) Table 72. Global Treatment for Accelerated-Phase CML Sales Market Share by Region (2027-2032) Table 73. Global Treatment for Accelerated-Phase CML Revenue by Region (2021-2026) & (US$ Million) Table 74. Global Treatment for Accelerated-Phase CML Revenue Market Share by Region (2021-2026) Table 75. Global Treatment for Accelerated-Phase CML Revenue by Region (2027-2032) & (US$ Million) Table 76. Global Treatment for Accelerated-Phase CML Revenue Market Share by Region (2027-2032) Table 77. North America Treatment for Accelerated-Phase CML Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America Treatment for Accelerated-Phase CML Sales by Country (2021-2026) & (K Units) Table 79. North America Treatment for Accelerated-Phase CML Sales by Country (2027-2032) & (K Units) Table 80. North America Treatment for Accelerated-Phase CML Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Treatment for Accelerated-Phase CML Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe Treatment for Accelerated-Phase CML Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe Treatment for Accelerated-Phase CML Sales by Country (2021-2026) & (K Units) Table 84. Europe Treatment for Accelerated-Phase CML Sales by Country (2027-2032) & (K Units) Table 85. Europe Treatment for Accelerated-Phase CML Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Treatment for Accelerated-Phase CML Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific Treatment for Accelerated-Phase CML Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific Treatment for Accelerated-Phase CML Sales by Country (2021-2026) & (K Units) Table 89. Asia Pacific Treatment for Accelerated-Phase CML Sales by Country (2027-2032) & (K Units) Table 90. Asia Pacific Treatment for Accelerated-Phase CML Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific Treatment for Accelerated-Phase CML Revenue by Country (2027-2032) & (US$ Million) Table 92. South America Treatment for Accelerated-Phase CML Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America Treatment for Accelerated-Phase CML Sales by Country (2021-2026) & (K Units) Table 94. South America Treatment for Accelerated-Phase CML Sales by Country (2027-2032) & (K Units) Table 95. South America Treatment for Accelerated-Phase CML Revenue by Country (2021-2026) & (US$ Million) Table 96. South America Treatment for Accelerated-Phase CML Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa Treatment for Accelerated-Phase CML Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa Treatment for Accelerated-Phase CML Sales by Country (2021-2026) & (K Units) Table 99. Middle East and Africa Treatment for Accelerated-Phase CML Sales by Country (2027-2032) & (K Units) Table 100. Middle East and Africa Treatment for Accelerated-Phase CML Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa Treatment for Accelerated-Phase CML Revenue by Country (2027-2032) & (US$ Million) Table 102. Global Treatment for Accelerated-Phase CML Sales by Type (2021-2026) & (K Units) Table 103. Global Treatment for Accelerated-Phase CML Sales by Type (2027-2032) & (K Units) Table 104. Global Treatment for Accelerated-Phase CML Sales Market Share by Type (2021-2026) Table 105. Global Treatment for Accelerated-Phase CML Sales Market Share by Type (2027-2032) Table 106. Global Treatment for Accelerated-Phase CML Revenue by Type (2021-2026) & (US$ Million) Table 107. Global Treatment for Accelerated-Phase CML Revenue by Type (2027-2032) & (US$ Million) Table 108. Global Treatment for Accelerated-Phase CML Revenue Market Share by Type (2021-2026) Table 109. Global Treatment for Accelerated-Phase CML Revenue Market Share by Type (2027-2032) Table 110. Global Treatment for Accelerated-Phase CML Price by Type (2021-2026) & (US$/Unit) Table 111. Global Treatment for Accelerated-Phase CML Price by Type (2027-2032) & (US$/Unit) Table 112. Global Treatment for Accelerated-Phase CML Sales by Application (2021-2026) & (K Units) Table 113. Global Treatment for Accelerated-Phase CML Sales by Application (2027-2032) & (K Units) Table 114. Global Treatment for Accelerated-Phase CML Sales Market Share by Application (2021-2026) Table 115. Global Treatment for Accelerated-Phase CML Sales Market Share by Application (2027-2032) Table 116. Global Treatment for Accelerated-Phase CML Revenue by Application (2021-2026) & (US$ Million) Table 117. Global Treatment for Accelerated-Phase CML Revenue by Application (2027-2032) & (US$ Million) Table 118. Global Treatment for Accelerated-Phase CML Revenue Market Share by Application (2021-2026) Table 119. Global Treatment for Accelerated-Phase CML Revenue Market Share by Application (2027-2032) Table 120. Global Treatment for Accelerated-Phase CML Price by Application (2021-2026) & (US$/Unit) Table 121. Global Treatment for Accelerated-Phase CML Price by Application (2027-2032) & (US$/Unit) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Treatment for Accelerated-Phase CML Distributors List Table 125. Treatment for Accelerated-Phase CML Customers List Table 126. Treatment for Accelerated-Phase CML Industry Trends Table 127. Treatment for Accelerated-Phase CML Industry Drivers Table 128. Treatment for Accelerated-Phase CML Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Treatment for Accelerated-Phase CML Product Image Figure 5. Global Treatment for Accelerated-Phase CML Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Treatment for Accelerated-Phase CML Market Size (2021-2032) & (US$ Million) Figure 7. Global Treatment for Accelerated-Phase CML Sales (2021-2032) & (K Units) Figure 8. Global Treatment for Accelerated-Phase CML Average Price (US$/Unit) & (2021-2032) Figure 9. Tyrosine Kinase Inhibitors Product Image Figure 10. Allogeneic Stem Cell Transplantation Product Image Figure 11. Others Product Image Figure 12. Hospitals Product Image Figure 13. Clinics Product Image Figure 14. Others Product Image Figure 15. Global Treatment for Accelerated-Phase CML Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Treatment for Accelerated-Phase CML, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Treatment for Accelerated-Phase CML Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Treatment for Accelerated-Phase CML Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Treatment for Accelerated-Phase CML Sales by Region in 2025 Figure 21. Global Treatment for Accelerated-Phase CML Revenue by Region in 2025 Figure 22. North America Treatment for Accelerated-Phase CML Market Size by Country in 2025 Figure 23. North America Treatment for Accelerated-Phase CML Sales Market Share by Country (2021-2032) Figure 24. North America Treatment for Accelerated-Phase CML Revenue Market Share by Country (2021-2032) Figure 25. United States Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Treatment for Accelerated-Phase CML Market Size by Country in 2025 Figure 29. Europe Treatment for Accelerated-Phase CML Sales Market Share by Country (2021-2032) Figure 30. Europe Treatment for Accelerated-Phase CML Revenue Market Share by Country (2021-2032) Figure 31. Germany Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Treatment for Accelerated-Phase CML Market Size by Country in 2025 Figure 42. Asia Pacific Treatment for Accelerated-Phase CML Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Treatment for Accelerated-Phase CML Revenue Market Share by Country (2021-2032) Figure 44. China Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Treatment for Accelerated-Phase CML Market Size by Country in 2025 Figure 53. South America Treatment for Accelerated-Phase CML Sales Market Share by Country (2021-2032) Figure 54. South America Treatment for Accelerated-Phase CML Revenue Market Share by Country (2021-2032) Figure 55. Brazil Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Colombia Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Treatment for Accelerated-Phase CML Market Size by Country in 2025 Figure 60. Middle East and Africa Treatment for Accelerated-Phase CML Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Treatment for Accelerated-Phase CML Revenue Market Share by Country (2021-2032) Figure 62. Egypt Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Treatment for Accelerated-Phase CML Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Treatment for Accelerated-Phase CML Sales Market Share by Type (2021-2032) Figure 68. Global Treatment for Accelerated-Phase CML Revenue Market Share by Type (2021-2032) Figure 69. Global Treatment for Accelerated-Phase CML Price (US$/Unit) by Type (2021-2032) Figure 70. Global Treatment for Accelerated-Phase CML Sales Market Share by Application (2021-2032) Figure 71. Global Treatment for Accelerated-Phase CML Revenue Market Share by Application (2021-2032) Figure 72. Global Treatment for Accelerated-Phase CML Price (US$/Unit) by Application (2021-2032) Figure 73. Treatment for Accelerated-Phase CML Value Chain Figure 74. Treatment for Accelerated-Phase CML Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Treatment for Accelerated-Phase CML Industry Opportunities and Challenges

Scope & coverage.

Types
  • Tyrosine Kinase Inhibitors
  • Allogeneic Stem Cell Transplantation
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Apotex
  • Bristol Myers Squibb
  • Dr. Reddy's Laboratories
  • Novartis
  • Pfizer
  • Takeda Pharmaceuticals
  • Lunan Pharmaceutical
  • Qilu Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Treatment for Accelerated-Phase CML Market Size (2021-2032)
  4. 2.2.2 Global Treatment for Accelerated-Phase CML Sales (2021-2032)
  5. 2.2.3 Global Treatment for Accelerated-Phase CML Market Average Price (2021-2032)
  6. 2.3 Treatment for Accelerated-Phase CML by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Tyrosine Kinase Inhibitors
  9. 2.3.3 Allogeneic Stem Cell Transplantation
  10. 2.3.4 Others
  11. 2.4 Treatment for Accelerated-Phase CML by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospitals
  14. 2.4.3 Clinics
  15. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Treatment for Accelerated-Phase CML Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Treatment for Accelerated-Phase CML Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Treatment for Accelerated-Phase CML Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Treatment for Accelerated-Phase CML Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Treatment for Accelerated-Phase CML Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Treatment for Accelerated-Phase CML, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Treatment for Accelerated-Phase CML, Product Type & Application
  8. 3.8 Global Manufacturers of Treatment for Accelerated-Phase CML, Established Date
  9. 3.9 Global Treatment for Accelerated-Phase CML Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Apotex
  2. 4.1.1 Apotex Company Information
  3. 4.1.2 Apotex Business Overview
  4. 4.1.3 Apotex Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Apotex Treatment for Accelerated-Phase CML Product Portfolio
  6. 4.1.5 Apotex Recent Developments
  7. 4.2 Bristol Myers Squibb
  8. 4.2.1 Bristol Myers Squibb Company Information
  9. 4.2.2 Bristol Myers Squibb Business Overview
  10. 4.2.3 Bristol Myers Squibb Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bristol Myers Squibb Treatment for Accelerated-Phase CML Product Portfolio
  12. 4.2.5 Bristol Myers Squibb Recent Developments
  13. 4.3 Dr. Reddy's Laboratories
  14. 4.3.1 Dr. Reddy's Laboratories Company Information
  15. 4.3.2 Dr. Reddy's Laboratories Business Overview
  16. 4.3.3 Dr. Reddy's Laboratories Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Dr. Reddy's Laboratories Treatment for Accelerated-Phase CML Product Portfolio
  18. 4.3.5 Dr. Reddy's Laboratories Recent Developments
  19. 4.4 Novartis
  20. 4.4.1 Novartis Company Information
  21. 4.4.2 Novartis Business Overview
  22. 4.4.3 Novartis Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis Treatment for Accelerated-Phase CML Product Portfolio
  24. 4.4.5 Novartis Recent Developments
  25. 4.5 Pfizer
  26. 4.5.1 Pfizer Company Information
  27. 4.5.2 Pfizer Business Overview
  28. 4.5.3 Pfizer Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Pfizer Treatment for Accelerated-Phase CML Product Portfolio
  30. 4.5.5 Pfizer Recent Developments
  31. 4.6 Takeda Pharmaceuticals
  32. 4.6.1 Takeda Pharmaceuticals Company Information
  33. 4.6.2 Takeda Pharmaceuticals Business Overview
  34. 4.6.3 Takeda Pharmaceuticals Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Takeda Pharmaceuticals Treatment for Accelerated-Phase CML Product Portfolio
  36. 4.6.5 Takeda Pharmaceuticals Recent Developments
  37. 4.7 Lunan Pharmaceutical
  38. 4.7.1 Lunan Pharmaceutical Company Information
  39. 4.7.2 Lunan Pharmaceutical Business Overview
  40. 4.7.3 Lunan Pharmaceutical Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lunan Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio
  42. 4.7.5 Lunan Pharmaceutical Recent Developments
  43. 4.8 Qilu Pharmaceutical
  44. 4.8.1 Qilu Pharmaceutical Company Information
  45. 4.8.2 Qilu Pharmaceutical Business Overview
  46. 4.8.3 Qilu Pharmaceutical Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Qilu Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio
  48. 4.8.5 Qilu Pharmaceutical Recent Developments
  49. 4.9 CSPC Ouyi Pharmaceutical
  50. 4.9.1 CSPC Ouyi Pharmaceutical Company Information
  51. 4.9.2 CSPC Ouyi Pharmaceutical Business Overview
  52. 4.9.3 CSPC Ouyi Pharmaceutical Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 CSPC Ouyi Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio
  54. 4.9.5 CSPC Ouyi Pharmaceutical Recent Developments
  55. 4.10 Chia Tai Tianqing Pharmaceutical
  56. 4.10.1 Chia Tai Tianqing Pharmaceutical Company Information
  57. 4.10.2 Chia Tai Tianqing Pharmaceutical Business Overview
  58. 4.10.3 Chia Tai Tianqing Pharmaceutical Treatment for Accelerated-Phase CML Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Chia Tai Tianqing Pharmaceutical Treatment for Accelerated-Phase CML Product Portfolio
  60. 4.10.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global Treatment for Accelerated-Phase CML Market Scenario by Region
  1. 5.1 Global Treatment for Accelerated-Phase CML Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Treatment for Accelerated-Phase CML Sales by Region: 2021-2032
  3. 5.2.1 Global Treatment for Accelerated-Phase CML Sales by Region: 2021-2026
  4. 5.2.2 Global Treatment for Accelerated-Phase CML Sales by Region: 2027-2032
  5. 5.3 Global Treatment for Accelerated-Phase CML Revenue by Region: 2021-2032
  6. 5.3.1 Global Treatment for Accelerated-Phase CML Revenue by Region: 2021-2026
  7. 5.3.2 Global Treatment for Accelerated-Phase CML Revenue by Region: 2027-2032
  8. 5.4 North America Treatment for Accelerated-Phase CML Market Facts & Figures by Country
  9. 5.4.1 North America Treatment for Accelerated-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Treatment for Accelerated-Phase CML Sales by Country (2021-2032)
  11. 5.4.3 North America Treatment for Accelerated-Phase CML Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Treatment for Accelerated-Phase CML Market Facts & Figures by Country
  16. 5.5.1 Europe Treatment for Accelerated-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Treatment for Accelerated-Phase CML Sales by Country (2021-2032)
  18. 5.5.3 Europe Treatment for Accelerated-Phase CML Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Treatment for Accelerated-Phase CML Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Treatment for Accelerated-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Treatment for Accelerated-Phase CML Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Treatment for Accelerated-Phase CML Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Treatment for Accelerated-Phase CML Market Facts & Figures by Country
  41. 5.7.1 South America Treatment for Accelerated-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Treatment for Accelerated-Phase CML Sales by Country (2021-2032)
  43. 5.7.3 South America Treatment for Accelerated-Phase CML Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Treatment for Accelerated-Phase CML Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Treatment for Accelerated-Phase CML Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Treatment for Accelerated-Phase CML Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Treatment for Accelerated-Phase CML Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Treatment for Accelerated-Phase CML Sales by Type (2021-2032)
  2. 6.1.1 Global Treatment for Accelerated-Phase CML Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Treatment for Accelerated-Phase CML Sales Market Share by Type (2021-2032)
  4. 6.2 Global Treatment for Accelerated-Phase CML Revenue by Type (2021-2032)
  5. 6.2.1 Global Treatment for Accelerated-Phase CML Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Treatment for Accelerated-Phase CML Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Treatment for Accelerated-Phase CML Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Treatment for Accelerated-Phase CML Sales by Application (2021-2032)
  2. 7.1.1 Global Treatment for Accelerated-Phase CML Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Treatment for Accelerated-Phase CML Sales Market Share by Application (2021-2032)
  4. 7.2 Global Treatment for Accelerated-Phase CML Revenue by Application (2021-2032)
  5. 7.2.1 Global Treatment for Accelerated-Phase CML Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Treatment for Accelerated-Phase CML Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Treatment for Accelerated-Phase CML Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Treatment for Accelerated-Phase CML Value Chain Analysis
  2. 8.1.1 Treatment for Accelerated-Phase CML Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Treatment for Accelerated-Phase CML Production Mode & Process
  5. 8.2 Treatment for Accelerated-Phase CML Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Treatment for Accelerated-Phase CML Distributors
  8. 8.2.3 Treatment for Accelerated-Phase CML Customers
9 Global Treatment for Accelerated-Phase CML Analyzing Market Dynamics
  1. 9.1 Treatment for Accelerated-Phase CML Industry Trends
  2. 9.2 Treatment for Accelerated-Phase CML Industry Drivers
  3. 9.3 Treatment for Accelerated-Phase CML Industry Opportunities and Challenges
  4. 9.4 Treatment for Accelerated-Phase CML Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst